Wak­ing up from some big block­buster dreams, Pfiz­er scraps a $250M drug deal as da­ta sour, safe­ty fears rise

A lit­tle over 2 years af­ter Pfiz­er paid Io­n­is $250 mil­lion cash to in-li­cense rights to vu­panors­en (AKCEA-ANGPTL3-LRx) — im­me­di­ate­ly vault­ing the drug on­to its list …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER